O	0	8	Clinical	Clinical	JJ	B-NP
O	9	21	significance	significance	NN	I-NP
O	22	24	of	of	IN	B-PP
B-Organism_substance	25	31	plasma	plasma	NN	B-NP
O	32	42	endostatin	endostatin	NN	I-NP
O	43	45	in	in	IN	B-PP
B-Cancer	46	51	acute	acute	JJ	B-NP
I-Cancer	52	59	myeloid	myeloid	JJ	I-NP
I-Cancer	60	68	leukemia	leukemia	NN	I-NP
O	68	69	/	/	SYM	B-NP
O	69	84	myelodysplastic	myelodysplastic	JJ	I-NP
O	85	93	syndrome	syndrome	NN	I-NP
O	93	94	.	.	.	O

O	95	105	BACKGROUND	BACKGROUND	NN	B-NP
O	105	106	:	:	:	O
O	107	117	Endostatin	Endostatin	NN	B-NP
O	117	118	,	,	,	O
O	119	120	a	a	DT	B-NP
O	121	122	C	C	NN	I-NP
O	122	123	-	-	HYPH	B-NP
O	123	131	terminal	terminal	JJ	I-NP
O	132	140	fragment	fragment	NN	I-NP
O	141	143	of	of	IN	B-PP
O	144	152	collagen	collagen	NN	B-NP
O	153	158	XVIII	XVIII	NN	I-NP
O	158	159	,	,	,	O
O	160	162	is	be	VBZ	B-VP
O	163	165	an	an	DT	B-NP
O	166	176	endogenous	endogenous	JJ	I-NP
O	177	189	angiogenesis	angiogenesis	NN	I-NP
O	190	199	inhibitor	inhibitor	NN	I-NP
O	199	200	.	.	.	O

O	201	206	While	While	IN	B-SBAR
O	207	217	endostatin	endostatin	NN	B-NP
O	218	220	is	be	VBZ	B-VP
O	221	226	being	be	VBG	I-VP
O	227	239	investigated	investigate	VBN	I-VP
O	240	243	for	for	IN	B-PP
O	244	247	its	its	PRP$	B-NP
O	248	258	usefulness	usefulness	NN	I-NP
O	259	261	in	in	IN	B-PP
O	262	270	treating	treat	VBG	B-VP
B-Cancer	271	276	solid	solid	JJ	B-NP
I-Cancer	277	283	tumors	tumor	NNS	I-NP
O	283	284	,	,	,	O
O	285	288	its	its	PRP$	B-NP
O	289	301	significance	significance	NN	I-NP
O	302	304	in	in	IN	B-PP
B-Cancer	305	316	hematologic	hematologic	JJ	B-NP
I-Cancer	317	329	malignancies	malignancy	NNS	I-NP
O	330	332	is	be	VBZ	B-VP
O	333	340	unknown	unknown	JJ	B-ADJP
O	340	341	.	.	.	O

O	342	349	METHODS	METHODS	NNS	B-NP
O	349	350	:	:	:	O
O	351	354	The	The	DT	B-NP
O	355	362	authors	author	NNS	I-NP
O	363	372	evaluated	evaluate	VBD	B-VP
B-Organism_substance	373	379	plasma	plasma	NN	B-NP
O	380	390	endostatin	endostatin	NN	I-NP
O	391	392	(	(	(	O
O	392	394	PE	PE	NN	B-NP
O	394	395	)	)	)	O
O	396	402	levels	level	NNS	B-NP
O	403	408	using	use	VBG	B-VP
O	409	411	an	an	DT	B-NP
O	412	418	enzyme	enzyme	NN	I-NP
O	419	425	linked	link	VBN	I-NP
O	426	437	immunoassay	immunoassay	NN	I-NP
O	438	440	in	in	IN	B-PP
O	441	443	71	71	CD	B-NP
O	444	452	patients	patient	NNS	I-NP
O	453	457	with	with	IN	B-PP
B-Cancer	458	463	acute	acute	JJ	B-NP
I-Cancer	464	471	myeloid	myeloid	JJ	I-NP
I-Cancer	472	480	leukemia	leukemia	NN	I-NP
O	481	482	(	(	(	O
B-Cancer	482	485	AML	AML	NN	B-NP
O	485	486	)	)	)	O
O	487	490	and	and	CC	O
O	491	493	43	43	CD	B-NP
O	494	502	patients	patient	NNS	I-NP
O	503	507	with	with	IN	B-PP
O	508	523	myelodysplastic	myelodysplastic	JJ	B-NP
O	524	532	syndrome	syndrome	NN	I-NP
O	533	534	(	(	(	O
O	534	537	MDS	MDS	NN	B-NP
O	537	538	)	)	)	O
O	538	539	,	,	,	O
O	540	543	and	and	CC	O
O	544	554	correlated	correlate	VBD	B-VP
O	555	557	PE	PE	NN	B-NP
O	558	562	with	with	IN	B-PP
O	563	570	various	various	JJ	B-NP
O	571	579	clinical	clinical	JJ	I-NP
O	580	590	parameters	parameter	NNS	I-NP
O	590	591	.	.	.	O

O	592	599	RESULTS	RESULTS	NNS	B-NP
O	599	600	:	:	:	O
O	601	606	There	There	EX	B-NP
O	607	610	was	be	VBD	B-VP
O	611	613	no	no	DT	B-NP
O	614	625	significant	significant	JJ	I-NP
O	626	636	difference	difference	NN	I-NP
O	637	639	in	in	IN	B-PP
O	640	643	the	the	DT	B-NP
O	644	650	median	median	JJ	I-NP
O	651	653	PE	PE	NN	I-NP
O	654	659	level	level	NN	I-NP
O	660	667	between	between	IN	B-PP
B-Cancer	668	671	AML	AML	NN	B-NP
O	671	672	/	/	SYM	B-VP
O	672	675	MDS	MDS	NN	B-NP
O	676	684	patients	patient	NNS	I-NP
O	685	688	and	and	CC	O
O	689	692	the	the	DT	B-NP
O	693	699	normal	normal	JJ	I-NP
O	700	708	controls	control	NNS	I-NP
O	708	709	.	.	.	O

O	710	722	Nevertheless	Nevertheless	RB	B-ADVP
O	722	723	,	,	,	O
O	724	732	patients	patient	NNS	B-NP
O	733	736	who	who	WP	B-NP
O	737	745	achieved	achieve	VBD	B-VP
O	746	754	complete	complete	JJ	B-NP
O	755	764	remission	remission	NN	I-NP
O	765	766	(	(	(	O
O	766	768	CR	CR	NN	B-NP
O	768	769	)	)	)	O
O	770	773	had	have	VBD	B-VP
O	774	775	a	a	DT	B-NP
O	776	789	significantly	significantly	RB	I-NP
O	790	795	lower	low	JJR	I-NP
O	796	802	median	median	JJ	I-NP
O	803	805	PE	PE	NN	I-NP
O	806	811	level	level	NN	I-NP
O	812	820	compared	compare	VBN	B-VP
O	821	823	to	to	TO	B-PP
O	824	829	those	those	DT	B-NP
O	830	833	who	who	WP	B-NP
O	834	837	did	do	VBD	B-VP
O	838	841	not	not	RB	O
O	841	842	.	.	.	O

O	843	845	In	In	IN	B-PP
O	846	858	multivariate	multivariate	JJ	B-NP
O	859	867	analysis	analysis	NN	I-NP
O	867	868	,	,	,	O
O	869	871	PE	PE	NN	B-NP
O	872	875	was	be	VBD	B-VP
O	876	881	found	find	VBN	I-VP
O	882	884	to	to	TO	I-VP
O	885	887	be	be	VB	I-VP
O	888	889	a	a	DT	B-NP
O	890	901	significant	significant	JJ	I-NP
O	902	903	(	(	(	O
O	903	904	P	P	NN	B-NP
O	905	906	=	=	SYM	B-VP
O	907	908	0	0	CD	B-NP
O	908	909	.	.	.	O
O	909	911	03	03	CD	O
O	911	912	)	)	)	O
O	913	922	predictor	predictor	NN	B-NP
O	923	925	of	of	IN	B-PP
O	926	933	overall	overall	JJ	B-NP
O	934	942	survival	survival	NN	I-NP
O	943	944	(	(	(	O
O	944	946	OS	OS	NN	B-NP
O	946	947	)	)	)	O
O	948	952	with	with	IN	B-PP
O	953	963	adjustment	adjustment	NN	B-NP
O	964	966	of	of	IN	B-PP
O	967	970	the	the	DT	B-NP
O	971	976	other	other	JJ	I-NP
O	977	985	baseline	baseline	NN	I-NP
O	986	996	covariates	covariate	NNS	I-NP
O	996	997	,	,	,	O
O	998	1007	including	include	VBG	B-PP
O	1008	1015	patient	patient	NN	B-NP
O	1016	1019	age	age	NN	I-NP
O	1019	1020	,	,	,	O
O	1021	1028	history	history	NN	B-NP
O	1029	1031	of	of	IN	B-PP
O	1032	1042	antecedent	antecedent	JJ	B-NP
B-Organism_substance	1043	1054	hematologic	hematologic	JJ	I-NP
O	1055	1064	disorders	disorder	NNS	I-NP
O	1064	1065	,	,	,	O
O	1066	1069	and	and	CC	O
O	1070	1073	the	the	DT	B-NP
O	1074	1077	use	use	NN	I-NP
O	1078	1080	of	of	IN	B-PP
O	1081	1091	protective	protective	JJ	B-NP
O	1092	1104	environments	environment	NNS	I-NP
O	1104	1105	.	.	.	O

O	1106	1109	The	The	DT	B-NP
O	1110	1120	prognostic	prognostic	JJ	I-NP
O	1121	1126	value	value	NN	I-NP
O	1127	1129	of	of	IN	B-PP
O	1130	1132	PE	PE	NN	B-NP
O	1133	1136	was	be	VBD	B-VP
O	1137	1141	also	also	RB	I-VP
O	1142	1151	evaluated	evaluate	VBN	I-VP
O	1152	1154	by	by	IN	B-PP
O	1155	1163	dividing	divide	VBG	B-VP
O	1164	1167	MDS	MDS	NN	B-NP
O	1167	1168	/	/	SYM	B-VP
B-Cancer	1168	1171	AML	AML	NN	B-NP
O	1172	1180	patients	patient	NNS	I-NP
O	1181	1185	into	into	IN	B-PP
O	1186	1190	high	high	JJ	B-NP
O	1191	1194	and	and	CC	I-NP
O	1195	1198	low	low	JJ	I-NP
O	1199	1201	PE	PE	NN	I-NP
O	1202	1208	groups	group	NNS	I-NP
O	1209	1214	using	use	VBG	B-VP
O	1215	1218	the	the	DT	B-NP
O	1219	1225	median	median	JJ	I-NP
O	1226	1228	PE	PE	NN	I-NP
O	1229	1234	level	level	NN	I-NP
O	1235	1237	of	of	IN	B-PP
O	1238	1244	normal	normal	JJ	B-NP
O	1245	1253	controls	control	NNS	I-NP
O	1254	1256	as	as	IN	B-SBAR
O	1257	1260	the	the	DT	B-NP
O	1261	1264	cut	cut	VB	I-NP
O	1264	1265	-	-	HYPH	B-VP
O	1265	1268	off	off	RP	B-PRT
O	1268	1269	.	.	.	O

O	1270	1273	The	The	DT	B-NP
O	1274	1281	authors	author	NNS	I-NP
O	1282	1287	found	find	VBD	B-VP
O	1288	1292	that	that	IN	B-SBAR
O	1293	1301	patients	patient	NNS	B-NP
O	1302	1304	in	in	IN	B-PP
O	1305	1308	the	the	DT	B-NP
O	1309	1313	high	high	JJ	I-NP
O	1314	1316	PE	PE	NN	I-NP
O	1317	1322	group	group	NN	I-NP
O	1323	1331	survived	survive	VBD	B-VP
O	1332	1335	for	for	IN	B-PP
O	1336	1337	a	a	DT	B-NP
O	1338	1351	significantly	significantly	RB	I-NP
O	1352	1359	shorter	short	JJR	I-NP
O	1360	1364	time	time	NN	I-NP
O	1365	1369	than	than	IN	B-PP
O	1370	1375	those	those	DT	B-NP
O	1376	1384	patients	patient	NNS	I-NP
O	1385	1387	in	in	IN	B-PP
O	1388	1391	the	the	DT	B-NP
O	1392	1395	low	low	JJ	I-NP
O	1396	1398	PE	PE	NN	I-NP
O	1399	1404	group	group	NN	I-NP
O	1404	1405	.	.	.	O

O	1406	1417	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1417	1418	:	:	:	O
O	1419	1421	PE	PE	NN	B-NP
O	1422	1424	is	be	VBZ	B-VP
O	1425	1426	a	a	DT	B-NP
O	1427	1433	useful	useful	JJ	I-NP
O	1434	1444	prognostic	prognostic	JJ	I-NP
O	1445	1454	predictor	predictor	NN	I-NP
O	1455	1457	of	of	IN	B-PP
O	1458	1460	CR	CR	NN	B-NP
O	1461	1464	and	and	CC	I-NP
O	1465	1467	OS	OS	NN	I-NP
O	1468	1471	for	for	IN	B-PP
B-Cancer	1472	1475	AML	AML	NN	B-NP
O	1475	1476	/	/	SYM	B-NP
O	1476	1479	MDS	MDS	NN	B-NP
O	1480	1488	patients	patient	NNS	I-NP
O	1488	1489	.	.	.	O

O	1490	1493	The	The	DT	B-NP
O	1494	1503	mechanism	mechanism	NN	I-NP
O	1504	1514	underlying	underlie	VBG	B-VP
O	1515	1518	the	the	DT	B-NP
O	1519	1530	association	association	NN	I-NP
O	1531	1538	between	between	IN	B-PP
O	1539	1543	high	high	JJ	B-NP
O	1544	1546	PE	PE	NN	I-NP
O	1547	1550	and	and	CC	O
O	1551	1555	poor	poor	JJ	B-NP
O	1556	1564	clinical	clinical	JJ	I-NP
O	1565	1572	outcome	outcome	NN	I-NP
O	1573	1575	is	be	VBZ	B-VP
O	1576	1583	unclear	unclear	JJ	B-ADJP
O	1583	1584	,	,	,	O
O	1585	1593	although	although	IN	B-SBAR
O	1594	1596	it	it	PRP	B-NP
O	1597	1600	may	may	MD	B-VP
O	1601	1603	be	be	VB	I-VP
O	1604	1611	related	related	JJ	B-ADJP
O	1612	1614	to	to	TO	B-PP
O	1615	1618	the	the	DT	B-NP
O	1619	1627	possible	possible	JJ	I-NP
O	1628	1630	PE	PE	NN	I-NP
O	1631	1641	reflection	reflection	NN	I-NP
O	1642	1644	of	of	IN	B-PP
B-Cancer	1645	1650	tumor	tumor	NN	B-NP
O	1651	1657	burden	burden	NN	I-NP
O	1657	1658	.	.	.	O

